Detalhe da pesquisa
1.
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients.
Am J Transplant
; 23(3): 423-428, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36906295
2.
SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.
Transfusion
; 63(7): 1354-1365, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37255467
3.
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.
Microbiol Spectr
; 12(1): e0328623, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38009954
4.
Early Treatment, Inflammation and Post-COVID Conditions.
medRxiv
; 2023 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36824860
5.
Early antibody treatment, inflammation, and risk of post-COVID conditions.
mBio
; 14(5): e0061823, 2023 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37724870
6.
Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study.
Lancet Microbe
; 4(9): e692-e703, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659419
7.
The effect of induction immunosuppression for kidney transplant on the latent HIV reservoir.
JCI Insight
; 7(21)2022 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36345940
8.
Erratum for Gebo et al., "Early antibody treatment, inflammation, and risk of post-COVID conditions".
mBio
; 15(1): e0297923, 2024 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38095433